Patients with chronic rhinosinusitis with nasal polyps saw improvements across all endpoints with tezepelumab, according to ...

short-term systemic corticosteroids for symptom exacerbations, and surgical removal of nasal polyps. Type 2 inflammation is driven by multiple cytokines, including interleukin-5 (IL-5).

The prevalence of chronic sinusitis in China is about 8 percent, meaning it affects approximately 107 million people, ...

Enrollment required a nasal polyp score of 5-8 and either 3 consecutive days of systemic steroid treatment in the past 2 years or any previous surgery for nasal polyps. Participants were randomly ...

The trial showed that treatment with the therapy decreased the severity of nasal polyps and congestion at week 52, as well as the need for surgery and the use of systemic corticosteroid. Severity of ...

Topical Corticosteroids The role of topical corticosteroids ... of the 3128 patients participating in this study had CRS. Patients without nasal polyps suffered less frequently from concomitant ...

For chronic rhinosinusitis with nasal polyps, at least 3% of adults reported headache, injection site reactions, arthralgia, upper abdominal pain, and dizziness. At least 3% of food allergy ...

Shares of OptiNose OPTN soared 52.5% on Thursday after the company announced that it is set to be acquired by Paratek ...

Paratek will accelerate access for XHANCE beyond specialists to primary care providers maximizing the recent label expansion for CRS in a ...

Phase 3 trials showed significant improvements in nasal polyp size and obstruction ... phenotype on medium- to high-dose inhaled corticosteroids (ICS) plus another asthma controller and, as ...

Nasal Polyps Treatment Market Research Report The global nasal polyps treatment market is expected to reach around $4,243.9 million by 2030 ...